yemenjmedYemen Journal of MedicinecoVolume 4 Issue 1MultidisciplinaryEnglishJanuary- April 2025NNY20250522ArticleOutcome of COVID-19 Positive Patients with type 2 Diabetes and Polypharmacy: an Examination of a Tertiary Hospital CohortEnglishY117122MohammedDanjuma1EnglishNBhagyaSree2EnglishYUnwamjumbo3EnglishYLina AlTarawneh4EnglishYRowanMesilhy4EnglishYAlyRoa4EnglishYHendAlObaidi4EnglishYAmal HElMasaad4EnglishYGamalAlFitori3EnglishYIslam Elzouki3  LinaNaseralallah2EnglishY5EnglishY10.63475/yjm.v4i1.0051Background: COVID-19-positive patients are at increased risk of adverse clinical outcomes, with type 2 diabetes cohorts at substantially higher risk compared to the general population. The additional role of diabetic and non-diabetic polypharmacy in these patients' clinical course has remained unexamined. In this study we have comprehensively examined the role of polypharmacy in the determination of mortality outcomes in patients with COVID-19 clinical syndrome.  Methods: We retrospectively examined case notes and electronic records of N = 497 patients with type 2 diabetes and COVID-19 infection. We ascertained the number of medications each patient was taking and used this to categorize the study cohort into diabetic [n = 246] (5 or more diabetic medications), and non-diabetic polypharmacy [n = 251] (5 or more non-diabetic medications). The primary outcome was the need for intensive care admission between the two groups.  Results: In patients with “non-diabetic polypharmacy” (>5 medications), advancing age, and higher HBA1c levels, were associated with increased risk of Intensive care admission (OR 1.06 [CI 1.03-1.07], P =EnglishCOVID-19, polypharmacy, Diabetes Mellitus, adverse drug reactionshttps://www.yemenjmed.com/admin/abstract?id=149References1619Rubin EJ, Baden LR, Abdool Karim SS, Morrissey S. Audio Interview: The Omicron Variant of SARS-CoV-2. New England Journal of Medicine. 2021; 385(23):e96.Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022; 602(7898):654-656McQueenie R, Foster HME, Jani BD, Katikireddi SV, Sattar N, Pell JP, et al. Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort. PLoS One. 2020; 15(8):e0238091.Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients with CPfizerand;rsquo;s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study: available at: https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidateand;nbsp; [Accessed on 23/12/2022]Cully M. A tale of two antiviral targets and;mdash; and the COVID-19 drugs that bind them. Nat Rev Drug Discov. 2022; 21(1):3-5.European Medicines Agency. EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation. Available at: https://www.ema.europa.eu/en/news/ema-endorses-use-dexamethasone-covid-19-patients-oxygen-or-mechanical-ventilation#:~:text=Based%20on%20the%20review%20of,(drip)%20into%20a%20vein. . [Accessed on 21/12/2022]Danjuma MI, Sinha U, Fatima H, Mohamed MFH, Nathoe H. QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine: A letter to the editor. Eur J Clin Invest. 2020; 50(11):e13407.Porter B, Arthur A, Savva GM. How do potentially inappropriate medications and polypharmacy affect mortality in frail and non-frail cognitively impaired older adults? A cohort study. BMJ Open. 2019; 9(5):e026171.Dhalwani NN, Fahami R, Sathanapally H, Seidu S, Davies MJ, Khunti K. Association between polypharmacy and falls in older adults: A longitudinal study from England. BMJ Open. 2017; 7(10):e016358.Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017; 17(1):230.Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes care. 2003; 26(5):1408and;ndash;12.da Silva MRR, Diniz LM, dos Santos JBR, Reis EA, da Mata AR, de Araand;uacute;jo VE, et al. Drug utilization and factors associated with polypharmacy in individuals with diabetes mellitus in Minas Gerais, Brazil. Ciencia e Saude Coletiva. 2018; 23(8): 2565-2574Kow CS, Hasan SS. Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: A meta-analysis. Journal of medical virology. J Med Virol. 2021; 93(2):695-697.Crouse A, Grimes T, Li P, Might M, Ovalle F, Shalev A. Metformin use is associated with reduced mortality in a diverse population withand;nbsp; COVID-19 and diabetes. Front Endocrinol. 2021;11: 600439..Jain V, Yuan JM. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. Int J Public Health. 2020;65(5): 533-546.Sirois C, Boiteau V, Chiu Y, Gilca R, Simard M. Exploring the associations between polypharmacy and COVID-19-related hospitalisations and deaths: a population-based cohort study among older adults in Quebec, Canada. BMJ open. 2022; 12(3):e060295.Do JY, Kim SW, Park JW, Cho KH, Kang SH. Is there an association between metformin use and clinical outcomes in diabetes patients with COVID-19? Diabetes Metab. 2021;47(4):101208Bramante CT, Ingraham NE, Murray TA, Marmor S, Hovertsen S, Gronski J, et al. Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis. Lancet Healthy Longev. 2021;2(1): e34-e41.Saand AR, Flores M, Kewan T, Alqaisi S, Alwakeel M, Griffiths L, et al. Does inpatient hyperglycemia predict a worse outcome in COVID-19 intensive care unit patients? J Diabetes. 2021;13(3): 253-260Esam Z. A proposed mechanism for the possible therapeutic potential of Metformin in COVID-19. Diabetes Res Clin Pract. 2020; 167:108282.Parray A, Mir FA, Doudin A, Iskandarani A, Danjuma MM, Kuni RAT, et al. SnoRNAs and miRNAs Networks Underlying COVID-19 Disease Severity. Vaccines (Basel). 2021; 9(10):105623. and;nbsp;and;nbsp;Gupta JK, Ravindrarajah R, Tilston G, Ollier W, Ashcroft DM, Heald AH. The association of polypharmacy with COVID-19 outcomes independent of comorbidities in people with type 2 diabetes: implications for the unforeseen consequences of polypharmacy. Cardiovasc Endocrinol Metab. 2024 May 23;13(2):e0304.and;nbsp;Formiga F, Vidal X, Agustand;iacute; A, Chivite D, Rosand;oacute;n B, Barband;eacute; J, et al. Potentially Inappropriate Prescription in Older Patients in Spain (PIPOPS) Investigatorsand;#39; Project. Inappropriate prescribing in elderly people with diabetes admitted to hospital. Diabet Med. 2016; 33(5):655-62Cheng X, Liu Y-M, Li H, Zhang X, Lei F, Qin J-J, et al. Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, inand;nbsp; Individuals with COVID-19 and Pre-existing Type 2 Diabetes. Cell metabolism. 2020; 32(4):537-547.e3Reiterer M, Rajan M, Gand;oacute;mez-Banoy N, Lau JD, Gomez-Escobar LG, Ma L, Gilani A, et al. Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2. Cell Metab. 2021; 33(11):2174-2188.e5Yang Y, Cai Z, Zhang J. Hyperglycemia at admission is a strong predictor of mortality and severe/critical complications in COVID-19 patients: a meta-analysis. Biosci Rep. 2021; 41(2):BSR20203584Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R, Klonoff DC. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. J Diabetes Sci Technol. 2020; 14(4):813-821.Tharmarajah E, Buazon A, Patel V, Hannah JR, Adas M, Allen VB, et al. IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression. J Infect. 2021; 82(5):178-185.Eljilany I, Elzouki AN. D-dimer, fibrinogen, and il-6 in covid-19 patients with suspected venous thromboembolism: A narrative review. Vol. 16, Vascular Health and Risk Management. 2020; 16:455-462Potere N, Batticciotto A, Vecchiand;eacute; A, Porreca E, Cappelli A, Abbate A, et al. The role of IL-6 and IL-6 blockade in COVID-19. Expert Review of Clinical Immunology. 2021; 17(6): 601-618Chen L, Sun W, Liu Y, Zhang L, Lv Y, Wang Q, et al. Association of Early-Phase In-Hospital Glycemic Fluctuation With Mortality in Adult Patients With Coronavirus Disease 2019. Diabetes Care. 2021;44(4): 865-873